Cellular Biomedicine Group opens new GMP facility in Beijing

Four independent production lines to support clinical batch production and commercial scale manufacturing.

“We feel this is the opportune time for this expansion into Beijing as we prepare for increasing manufacturing demands to supply cell therapy materials for more research and clinical trials from our immuno-oncology, especially CAR-T therapy, and mesenchymal progenitor cell (haMPC) programs,” said Dr Richard L. Wang, Chief Operating Officer for the company. Our multi-national team of seasoned scientists is proud to see the implementation of our vertically integrated research and development and production systems in several locations. With patented processes and technologies applied to every step of our cellular medicine platform spanning sample collection and processing, cell expansion, banking, shipping and application, we are able to deliver consistent quality measures across China, which we believe will better serve our patient population in the future.”